Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3481 - Early-stage diagnosis of pancreatic cancer offers opportunity to improve overall patient survival


10 Oct 2016


Poster display


Linda Dexlin Mellby


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


L. Dexlin Mellby1, A. Holmér2, C. Wingren3, J. Johansen4, S.E. Bojesen5, B.G. Nordestgaards55, C.A. Borrebaeck3

Author affiliations

  • 1 Immunovia Ab, Immunovia AB, 223 81 Lund - Lund/SE
  • 2 Immunovia Ab, Immunovia AB, Lund/SE
  • 3 Immunotechnology, Lund University, Lund/SE
  • 4 Department Of Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 5 Health And Medical Sciences, University of Copenhagen, Copenhagen/DK


Abstract 3481


Pancreatic ductal adenocarcinoma (PDAC) has one of the worst survival rates with only 5% five years survival. By providing physicians with actionable information when the tumour is still resectable, the overall 5 year PDAC patient survival rate could increase from 5 % to 50- 60%. We present a summary of retrospective studies performed on IMMray™ PanCan-d, a blood test developed for early stage diagnosis of pancreatic cancer.


IMMray™ PanCan-d creates a biological snapshot of an individual's immune response by analysing serum proteins that change as a sign of disease. The process to derive unique biomarker immunosignatures from an antibody microarray platform, through state of the art bioinformatics algorithms, is also presented.


Based on recent results from the largest retrospective study on pancreas cancer covering 1400 blood samples, we have been able to differentiate 148 asymptomatic patients in stage I and II from 890 healthy individuals controls with 96% accuracy*. Furthermore, when analyzing all stages of pancreatic cancer in retrospective studies covering more than 3000 blood samples, the test accuracy is as high as 98%. *Manuscript in preparation


IMMray PanCan-d can detect asymptomatic pancreatic cancer patients stage 1 and 2 with 96% accuracy and stage 1 to 4 with 98% accuracy.

Clinical trial identification

Legal entity responsible for the study

Lund University, Create Health, Dept. of Immunotechnology


Lund University, Create Health, Dept. of Immunotechnology


L. Dexlin Mellby, A. Holmér: Employee at Immunovia AB. All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings